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Inhibition of protein phosphatase 2A (PP2A)
activity has been identified as a prerequisite
for the transformation of human cells. However,
the molecular mechanisms by which PP2A
activity is inhibited in human cancers are
currently unclear. In this study, we describe
a cellular inhibitor of PP2A with oncogenic
activity. The protein, designated Cancerous
Inhibitor of PP2A (CIP2A), interacts directly
with the oncogenic transcription factor c-Myc,
inhibits PP2A activity toward c-Myc serine 62
(S62), and thereby prevents c-Myc proteolytic
degradation. In addition to its function in c-
Myc stabilization, CIP2A promotes anchorage-
independent cell growth and in vivo tumor
formation. The oncogenic activity of CIP2A is
demonstrated by transformation of human
cells by overexpression of CIP2A. Importantly,
CIP2A is overexpressed in two common human
malignancies, head and neck squamous cell
carcinoma (HNSCC) and colon cancer. Thus,
our data show that CIP2A is a human oncopro-
tein that inhibits PP2A and stabilizes c-Myc in
human malignancies.INTRODUCTION
Cancer is a complex and diverse set of diseases related to
the unharnessed growth, enhanced survival, and invasion
of cells (Hanahan andWeinberg, 2000). Although there are
various means to achieve cellular transformation, a limited
number of elements can suffice to transform many differ-
ent human cell types, suggesting that a discreet yet com-
mon set of pathways mediate this process (Hanahan and
Weinberg, 2000; Zhao et al., 2004). Experimentally, it has
been demonstrated that activation of Ras and telomerase,
along with inactivation of the tumor suppressor proteins
p53 and retinoblastoma protein (Rb) can immortalize a
variety of human cell types, which can subsequently trans-
form to a tumorigenic state only by inhibiting protein phos-
phatase 2A (PP2A) (Hahn et al., 1999; Janssens et al.,
2005; Rangarajan et al., 2004; Zhao et al., 2004).
PP2A is a widely conserved protein serine/threonine
phosphatase (PSP) that functions as a trimeric protein
complex consisting of a catalytic subunit (PP2Ac or C),
a scaffold subunit (PR65 or A), and one of the alternative
regulatory B subunits (Figure 1A) (Janssens and Goris,
2001). Inmammals, a and b isoforms exist for both the cat-
alytic (C) and scaffolding (PR65/A) subunits; in addition,
there are four B subunit families, each with several
isoforms or splice variants. Such variability in PP2A holo-
enzyme composition results in an amazingly diverse
enzyme with a vast array of substrate specificities.Cell 130, 51–62, July 13, 2007 ª2007 Elsevier Inc. 51
Figure 1. CIP2A Is a Novel PP2A-Inter-
acting Protein
(A) Schematic representation of the PP2A com-
plex composed of the PR65 scaffold subunit,
PP2Ac catalytic subunit, and a regulatory
B-subunit. TAP-tag, tandem affinity purification
tag.
(B) Silver-stained gel of eluates from mock or
PR65TAP stable cells following tandem affinity
purification. The bands unique to the PR65TAP
eluates were identified by tandem mass spec-
trometric analysis.
(C) Coimmunoprecipitation of endogenous
PR65 from cytosolic HeLa extracts reveals an
interaction between endogenous CIP2A,
PR65 and PP2Ac proteins. PI, preimmune
serum; input, input material.
(D) Confocal microscopy of endogenous PR65
and CIP2A in HeLa cells. Colocalization is
indicated by the yellow staining in the merge
image. Nuclear DNA was visualized with
DAPI.
(E) Immunoblotting with PR65 antibody from coimmunoprecipates of Flag-CIP2A deletion constructs was used to evaluate the presence of the PP2A
complex. The immmunoprecipitates were washed in 150mMNaCl concentration. Shown is a representative result of three independent experiments.
The lack of size differences between CIP2A deletions is due to the western blot running conditions disfavoring separation of the large size proteins. IP,
immunoprecipitation; 5%, 5% of the input material used for immunoprecipitation.Recent studies have identified target molecules for
which dephosphorylation is critical for the tumor suppres-
sor activity of PP2A (reviewed in Arroyo and Hahn, 2005;
Janssens and Goris, 2001; Janssens et al., 2005). In addi-
tion to protein kinases, PP2A regulates the function of
transcription factors involved in cellular transformation.
While regulation of p53 function by PP2A (Moule et al.,
2004; Okamoto et al., 2002) is not sufficient alone to pro-
mote cellular transformation (Arroyo and Hahn, 2005;
Rangarajan et al., 2004), dephosphorylation of the onco-
genic transcription factor c-Myc is critical for PP2A tumor
suppressor activity. Inhibition of PP2A activity induces
c-Myc serine 62 (S62) phosphorylation and c-Myc protein
stabilization (Arnold and Sears, 2006; Yeh et al., 2004).
Furthermore, it was shown that c-Myc S62 dephosphory-
lation inhibits cellular transformation and that inhibition of
PP2A-mediated c-Myc dephosphorylation can suffice for
SV40 small-t antigen in human transformation assays (Yeh
et al., 2004). Taken together, the studies summarized
above have established that inhibition of PP2A-mediated
c-Myc S62 dephosphorylation is one of the prerequisites
for human cell transformation. However, as the majority
of evidence supporting the role of PP2A as a tumor
suppressor has been obtained by using viral antigens or
chemical inhibitors (Hahn et al., 1999; Janssens et al.,
2005; Rangarajan et al., 2004; Yeh et al., 2004; Zhao
et al., 2004), the in vivo mechanisms by which PP2A
activity is inhibited in spontaneously transformed human
cancer cells are unclear.
In this work, we identify KIAA1524, also termed p90
(Soo Hoo et al., 2002), as an endogenous PP2A-interact-
ing protein from human cancer cells, which we named
Cancerous Inhibitor of PP2A (CIP2A). Our results show
that the protein inhibits PP2A activity toward c-Myc S6252 Cell 130, 51–62, July 13, 2007 ª2007 Elsevier Inc.and thereby stabilizes c-Myc protein. In addition, we
demonstrate that KIAA1524/p90/CIP2A, called CIP2A
hereafter, is required for the malignant cellular growth.
Moreover, overexpression of the protein transforms
immortalized human cells. Importantly, our results also
demonstrate overexpression of CIP2A in two common
human malignancies. Together, these results demon-
strate that CIP2A is a human oncoprotein that inhibits
PP2A in human malignancies.
RESULTS
Identification of CIP2A as an Endogenous
PP2A-Associated Protein
To identify PP2A-interacting proteins from human cancer
cells, cell clones stably expressing TAP-tagged PR65
protein, the 65 kDa scaffolding subunit of the PP2A com-
plex (Figure 1A), were generated. TAP purification from
cytoplasmic extracts of either mock transfected or
PR65TAP-expressing cells revealed several proteins that
only copurified with the PR65TAP (Figure 1B). Subse-
quently, the putative PR65-interacting proteins were iden-
tified by mass-spectrometric peptide sequencing. Among
the proteins identified were both the PP2A catalytic
subunit (PP2Ac) and a PP2A B55a subunit, thus validating
the approach (Figure 1B). In addition, a novel putative
PP2A-interacting protein, KIAA1524, was identified based
on seven unique matching peptides and a combined
Mascot score of 355 (Figure 1B and Table S1).
KIAA1524 is a 90 kDa cytoplasmic protein shown to be
expressed in gastric cancer tissue but with no previously
identified cellular function (Soo Hoo et al., 2002). Se-
quence analysis of KIAA1524 reveals no significant
homology to any protein with known function, although
the protein harbors several putative protein-protein inter-
action domains (Figure S1). In this work, we demonstrate
that KIAA1524 inhibits PP2A in humanmalignancies and is
therefore hereby designated as CIP2A.
To verify this interaction, coimmunoprecipitation analy-
ses were performed from cytoplasmic extracts of HeLa
cells using a PR65 antibody. Indeed, endogenous CIP2A
and PP2Ac coimmunoprecipitated with the endogenous
PR65 (Figure 1C). Moreover, confocal analysis of HeLa
cells revealed colocalization of CIP2A with PR65 in the
perinuclear region, in addition to cytoplasmic structures
(Figure 1D). As expected based on the previously pub-
lished data (Soo Hoo et al., 2002), CIP2A was primarily
cytoplasmic, although weak nuclear staining was de-
tected (Figure 1D and data not shown).
To strengthen the interaction data between CIP2A and
the PP2A complex, a series of Flag-tagged CIP2A deletion
constructs (Figure S1) were transiently transfected into
HeLa cells for 48 hr, followed by immunoprecipitation
with anti-Flag antibody. Importantly, no CIP2A antibody
immunoreactivity was detected in anti-Flag antibody
immunoprecipitates from the mock-transfected cells,
confirming the specificity of anti-Flag antibody for CIP2A-
deletion proteins in immunoprecipitation (data not shown).
Interaction between the CIP2A mutants and the PP2A
complex was assessed by western blot analysis of the
PR65 subunit. In either low (150 mM NaCl) or moderate
(300 mM NaCl) stringency conditions, Flag-CIP2A wild-
type (CIP2Awt) clearly coimmunoprecipitated with the
endogenous PR65 protein (Figure 1E and data not shown).
Moreover, CIP2A lacking the amino acids between 461and
533was the onlymutant out of 11 deletions (Figure S1) that
demonstrated impaired binding to PR65 in either strin-
gency condition (Figure 1E and data not shown).
These results identify CIP2A as an endogenous interac-
tion partner for the PP2A complex. Moreover, the data
show that amino acids between 461 and 533 on CIP2A
appear to be important for the interaction.
CIP2A Promotes c-Myc Protein Stability
Suppression of PP2A activity by either overexpression
of SV40 small-t antigen or by depletion of the B56g sub-
unit results in large changes in the genome-wide gene-
expression profile (Moreno et al., 2004). To probe for the
uncharacterized cellular functions of CIP2A, genome-
wide gene-expression profiles of scrambled and CIP2A
siRNA-transfected HeLa cells were compared after
72 hr. Remarkably, only a minor fraction of genes (76 out
of 26091) included in the Sentrix Human-6 Expression
BeadChip (Illumina, Inc.), showed a reproducible and
statistically significant (p < 0.05, data not shown) differ-
ence in their expression levels between scrambled and
CIP2A siRNA-transfected cells. As discussed above,
PP2A activity has been shown to regulate the activity of
two transformation-relevant transcription factors, p53
and c-Myc (Arroyo andHahn, 2005). To characterize these
two transcription factors in relation to the transcriptional
profile of CIP2A-depleted cells, the list of 76 genesaffected by CIP2A depletion was compared to target-
gene databases published for p53 and c-Myc. Based on
a p53 target-gene database (http://p53.bii.a-star.edu.sg/
aboutp53/targetgene/index.php), only 1 out of 76 genes
affected by CIP2A depletion has been published to harbor
a p53 binding site in its promoter or to be transcriptionally
regulated by p53. However, when compared with a c-Myc
target-gene database (http://www.myc-cancer-gene.org/
site/mycTargetDB.asp), 16% (12 out of 76) of genes
affected by CIP2A depletion were found to bind c-Myc
in their promoter region. These findings, together with
the published role of PP2A regulation of c-Myc protein
stability (Arnold and Sears, 2006; Yeh et al., 2004), sug-
gest that CIP2A may regulate c-Myc function.
To study this assumption, c-Myc protein steady-state
expression levels were evaluated from HeLa lysates
72 hr after transfection with CIP2A or scrambled siRNA.
Depletion of CIP2A resulted in a clear downregulation of
c-Myc protein expression (Figure 2A). Importantly, co-
transfection of siRNA-resistant CIP2A cDNA rescued
CIP2A protein levels and abolished c-Myc protein down-
regulation (Figure 2A). Moreover, two independent
CIP2A siRNAs suppressed c-Myc protein expression
(Figure 2B). These results demonstrate that CIP2A
supports c-Myc protein steady-state levels, whereas no
marked differences were observed in the expression or
phosphorylation status of other studied targets of PP2A
or of PP2Ac (Figure 2C).
Although depletion of CIP2A effectively reduced c-Myc
protein steady-state levels (Figures 2A—2C), c-Myc
mRNA expression was not significantly altered by CIP2A
depletion (Figure 2D), implying that CIP2A regulates
c-Myc protein levels posttranscriptionally, as does PP2A
(Arnold and Sears, 2006; Yeh et al., 2004). Indeed, the
analysis of half-life of endogenous c-Myc protein revealed
that CIP2A depletion reduced the stability of c-Myc
protein after cycloheximide treatment (100 mg/ml)
(Figure 2E). Quantification of c-Myc expression from three
independent experiments revealed a statistically signifi-
cant difference on c-Myc protein levels at 1–2 hr after
cycloheximide treatment (Figure 2F).
Together, these results demonstrate that CIP2A pro-
motes c-Myc protein stability in human cells.
CIP2A Inhibits c-Myc-Associated PP2A Activity
The results above demonstrate that CIP2A interacts with
the PP2A complex and promotes c-Myc stability, sug-
gesting that CIP2A may inhibit PP2A activity toward S62
on c-Myc (Arnold and Sears, 2006; Yeh et al., 2004). In
support of that, we found that CIP2A depletion reduced
c-Myc S62 phosphorylation relative to total c-Myc levels
in HeLa cells (Figure 3A). To study whether CIP2A indeed
inhibits c-Myc-associated PP2A activity, c-Myc immuno-
precipitates from scrambled and CIP2A siRNA-trans-
fected cells were subjected to an in vitro PP2A assay using
6,8-difluoro-4-methylumbelliferyl phosphate as the sub-
strate (Pastula et al., 2003). The specificity of the assay
conditions for detecting PP2A catalytic activity wasCell 130, 51–62, July 13, 2007 ª2007 Elsevier Inc. 53
Figure 2. CIP2A Stabilizes c-Myc Protein
(A) Western blot analysis of CIP2A, c-Myc, and PP2Ac expression levels from HeLa cells 72 hr after transfection with scrambled siRNA (Scr), CIP2A.1
siRNA (CIP2A), or both CIP2A.1 siRNA and a siRNA-resistant CIP2A cDNA.
(B) Western blot analysis of CIP2A and c-Myc expression levels fromHeLa cells 72 hr after transfection with two independent CIP2A-targeting siRNAs
(CIP2A.1 or CIP2A.2) or scrambled siRNA.
(C) Expression and phosphorylation of PP2A substrate proteins and PP2Ac from HeLa cells 72 hr after transfection with scrambled or CIP2A.1 siRNA.
Equal loading was verified with actin immoblotting. Shown is representative data from two to three independent experiments
(D) c-Myc and CIP2A mRNA expression levels 72 hr after transfection with scrambled or CIP2A.1 siRNA. Shown is mean +standard deviation (SD) of
two microarray experiments. n.s., not significant by Student’s t test. Similar results were obtained by northern blot analysis.
(E) c-Myc protein stability 72 hr posttransfection with scrambled and CIP2A.1 siRNA following cyclohexamide treatment (100 mg/ul) for the indicated
time points. Equal loading was verified with actin immoblotting.
(F) Quantitation of c-Myc protein levels 1–2 hr after cyclohexamide treatment from three independent experiments identical to shown in (E). Shown is
mean +SD of three experiments. *p <0.05, Student’s t test.demonstrated by inhibition of the phosphatase activity of
the purified PP2Ac-PP65 dimer and of c-Myc immunopre-
cipitate, by low nanomolar concentration of the PP2A
inhibitor okadaic acid (Figure S2). Interestingly, CIP2A
depletion clearly increased PP2A activity in c-Myc immu-
noprecipitates, whereas no increase in MDM2-associated
PP2A activity was observed in the same conditions
(Figure 3B). Importantly, the CIP2A siRNA-elicited
increase in c-Myc-associated PP2A activity was abol-
ished by cotransfection of siRNA-resistant CIP2A cDNA
(Figure 3B; siRNA rescue).
We previously demonstrated that the B56a subunit is
required for PP2A complex recruitment to c-Myc (Arnold
and Sears, 2006). To evaluate whether CIP2A affects the
PP2A recruitment to c-Myc, c-Myc was immunoprecipi-
tated from either CIP2A or scrambled siRNA-transfected
cells and analyzed for PP2Ac by western blotting. CIP2A
depletion did not affect the interaction between c-Myc
and PP2A, since PP2Ac can be coimmunoprecipitated
with c-Myc, regardless of CIP2A levels (Figure 3C; right
panel). These results confirm that endogenous CIP2A
and PP2Ac interact with c-Myc in HeLa cells and that
CIP2A does not inhibit c-Myc-associated PP2A activity
by preventing PP2Ac recruitment to c-Myc.54 Cell 130, 51–62, July 13, 2007 ª2007 Elsevier Inc.Coimmunoprecipitation of c-Myc and CIP2A from
cellular extracts demonstrates a physical association
between these proteins (Figure 3C) but does not reveal
whether the interaction between CIP2A and c-Myc is
direct. To further characterize CIP2A’s interaction with
c-Myc, purified Flag-CIP2A protein was used in an
in vitro protein-protein interaction assay with recombinant
GST-fused aminoterminal portion of c-Myc (aa 1–262).
We found that Flag-antibody resin coimmunoprecipitated
recombinant Flag-CIP2A and GST-Myc, whereas Flag-
CIP2A did not coimmunoprecipitate with GST alone
(Figure 3D), demonstrating that CIP2A directly binds to
the c-Myc aminoterminus. To further study the determi-
nants of CIP2A-c-Myc interaction, wild-type c-Myc
(WT) and mutants, where the aminoterminal PP2A target
S62 was mutated to either alanine (S62A) or aspartate
(S62D), were coexpressed in 293 cells with Flag-CIP2A.
Coimmunoprecipitation of Flag-CIP2A with V5-c-Myc
was thereafter studied by western blotting. Interestingly,
as compared to wild-type c-Myc, both S62 mutants dis-
played greatly reduced binding with CIP2A (Figure 3E),
whereas an alanine substitution of the adjacent threonine
58 did not inhibit the c-Myc-CIP2A interaction
(Figure S3).
Figure 3. CIP2A Inhibits c-Myc-Associ-
ated PP2A Activity
(A) Western blot analysis of c-Myc S62 phos-
phorylation and total c-Myc levels 72 hr after
treatment with scrambled or CIP2A.1 siRNA.
Levels were quantitated using LI-COR soft-
ware, and ratio of S62/total c-Myc was calcu-
lated. Shown is average +SD of three indepen-
dent experiments.
(B) The PP2A substrates c-Myc and MDM2
were immunoprecipitated from scrambled
siRNA (Scr), CIP2A.1 siRNA, or both CIP2A.1
siRNA and a siRNA-resistant CIP2A cDNA
(CIP2A rescue)-treated cells and analyzed for
PP2A activity. Shown are mean values mea-
sured in triplicate from a representative exper-
iment of two to three independent experiments.
(C) Coimmunoprecipitation of c-Myc from
cytosolic extracts of HeLa cells transfected
with scrambled or CIP2A.1 siRNA for 72 hr.
Left panel, input material; right panel, immuno-
precipitates.
(D) In vitro binding assay with immobilized,
recombinant Flag-CIP2A protein and recombi-
nant GST protein or with GST-c-Myc 1-262
protein. Immunoblots of eluates with GST
(top) or CIP2A (bottom). Input, GST proteins
used for interaction assay. Shown is a repre-
sentative blot of three independent experi-
ments with similar results.
(E) CIP2A binds to c-Myc through recognition
of c-Myc serine 62. 293 cells transiently
cotransfected for 48 hr with V5/His-c-Myc,
and Flag-CIP2A expression constructs were
subjected to immunoprecipitation by anti-V5
antibody. Immunoprecipitates were analyzed
by immunoblotting with the Flag (CIP2A) and
His-antibodies (c-Myc). Lower panel shows
input levels of Flag-CIP2A and V5/His-c-Myc.Together these experiments provide solid biochemical
evidence that CIP2A inhibits c-Myc-associated PP2A
activity and protects c-Myc S62 from dephosphorylation.
Moreover, direct binding of CIP2A to c-Myc aminotermi-
nus provides the most feasible explanation for the
observed selectivity of CIP2A toward c-Myc-associated
PP2A activity (Figures 2C and 3B).
CIP2A Is Required for Tumor Growth
Inhibition of PP2A activity increases cell proliferation and
supports cellular transformation (Arroyo and Hahn, 2005;
Chen et al., 2004). Therefore, the role of CIP2A in regulat-
ing cell proliferation was next analyzed by thymidine-
incorporation assay in HeLa cells. Compared to scram-
bled siRNA-transfected cells, CIP2A depletion resulted
in significant inhibition of cell proliferation 72 hr after trans-
fection (Figure 4A). However, CIP2A siRNA transfection
did not induce a sub-G1 fraction in fluorescence-activated
cell sorting (FACS) analysis of the cellular DNA content
(Figure 4B), nor did it induce cleavage of the PARP protein
(Figure 4C), demonstrating that CIP2A depletion does not
induce programmed cell death.To assess the contribution of CIP2A on the tumorigenic
potential of HeLa cells, the effects of CIP2A depletion on
the ability of these cells to form dense foci on amonolayer,
as well as their ability to grow in an anchorage-indepen-
dent manner, was analyzed. For this purpose, we first
studied the efficiency of CIP2A depletion by a single trans-
fection of siRNA 10 days after transfection and found very
potent reduction of CIP2A protein expression still after
10 days (Figure 4D). Importantly, CIP2A depletion abro-
gated HeLa cell foci formation 10 days after transfection
(Figure 4E) and also significantly impaired growth of
HeLa cells in soft agar (Figure 4F). In accordance with
results shown in Figure 2B, both CIP2A.1 and CIP2A.2
siRNAs identically reduced HeLa cell growth in soft agar
(Figure S4). To assess the tumorigenic role of CIP2A
in vivo, HeLa cells transfected with either CIP2A or scram-
bled siRNA for 72 hr were subcutaneously injected into
athymic mice and tumor growth was monitored by mea-
suring the size of palpable tumors. Importantly, depletion
of CIP2A by siRNA reduced the overall tumor size
(Figure 4G) and resulted in a significant inhibition of tumor
weight at day 27 (Figure 4H).Cell 130, 51–62, July 13, 2007 ª2007 Elsevier Inc. 55
Figure 4. CIP2A Is Required for Malig-
nant Growth and Tumorigenesis In Vivo
(A) Thymidine incorporation of HeLa cells trans-
fected for 72 hr with scrambled or CIP2A.1
siRNA for cell proliferation. Shown is mean +
S.D. of four experiments. *p < 0.05, Student’s
t test.
(B) Flow cytometric analysis of DNA content for
cell-cycle progression from HeLa cells trans-
fected with scrambled or CIP2A.1 siRNA for
72 hr. Results are from a representative exper-
iment of four repetitions with similar results.
(C) CIP2A depletion does not induce poly(ADP-
ribose) polymerase (PARP) cleavage in HeLa
cells as detected by immunoblotting 72 hr after
CIP2A.1 siRNA transfection. Shown is a rep-
resentative result of three independent
experiments. Expected molecular weights of
the full-length (110 kDa) and caspase-cleaved
forms of PARP proteins are shown on the right.
(D) Immunoblotting of CIP2A protein from HeLa
cells 4, 8, and 10 days after transfection with
scrambled or CIP2A.1 siRNA. Shown is a
representative result of three independent
experiments.
(E) Dense foci formation on a monolayer of
HeLa cells transfected with scrambled or
CIP2A.1 siRNA. Above, representative light
miscroscopy images. Below, quantitation of
number of foci 10 days after replating by Image
J software. Shown is average +SD of four
experiments. *p = 0.002, Student’s t test.
(F) Colony growth on soft agar of HeLa cells
transfected with scrambled or CIP2A siRNA.
Above, representative phase-contrast miscro-
scopy images. Below, quantitation of number
of colonies as measured 10 days after replating by Image J software. Shown is average +SD of four experiments. *p = 0.001, Student’s t test.
(G) 3 3 106 HeLa cells transfected with the indicated siRNA were injected 72 hr after transfection subcutaneously into the flank of immunocompro-
mised mice (scrambled siRNA n = 10 and CIP2A siRNA n = 8). Shown is mean + standard error of the mean (SEM) of tumor volumes in indicated time
points. The experiment was performed twice with similar results.
(H) Weights (mg) of tumors from the experiment shown in (G) at day 27. *p = 0.034, Mann-Whitney U test.Taken together, these data demonstrate that CIP2A
expression maintains a transformed cellular phenotype
and that CIP2A promotes in vivo tumor growth.
CIP2A Promotes Cell Transformation
To study if CIP2A has oncogenic properties when
expressed in nonmalignant cells, spontaneously immor-
talized mouse embryo fibroblasts (MEFs) were infected
with retroviral constructs encoding CIP2A and an onco-
genic form of Ras (RasV12), and the foci formation of the
infected cells on NIH-3T3 feeder layer was quantitated
14 days later. As expected, retroviral expression of
RasV12 did induce foci growth of immortalized MEFs
(Figure 5A). However, CIP2A expression alone did not
induce foci formation but did increase foci formation of
Ras-infected cells (Figure 5A), demonstrating that CIP2A
has oncogenic properties when expressed with Ras in
murine-immortalized fibroblasts.
The widely used human transformation model estab-
lished by Hahn and colleagues (Hahn et al., 1999, 2002)
was next utilized to analyze if CIP2A functions as an onco-56 Cell 130, 51–62, July 13, 2007 ª2007 Elsevier Inc.protein in human cells. Human embryonal kidney (HEK)
fibroblasts, in which p53 and the Rb family of tumor sup-
pressors have been inactivated and that express a cata-
lytic subunit of human telomerase (hTERT), along with on-
cogenic Ras (referred to as HEK-TERV cells), still require
inhibition of PP2A, for example by overexpression of
small-t antigen, for complete transformation (Hahn et al.,
1999, 2002). On the other hand, we have previously shown
that overexpression of the T58A c-Myc mutant, which is
resistant to PP2A-mediated dephosphorylation at S62,
can replace small-t antigen in HEK-TERV cell transforma-
tion (Yeh et al., 2004). Importantly, lentiviral overexpres-
sion of CIP2A in HEK-TERV cells resulted in cell transfor-
mation, thus demonstrating that CIP2A has oncogenic
potential (Figure 5B). It should be noted that although
the transformation capacity of CIP2A seems somewhat
reduced as compared to what has been published for
small-t antigen, it is comparable to other conditions in
which only a portion of the cellular PP2A complexes has
been inhibited, for example by depletion of B56g (Chen
et al., 2004, 2005; W.C. Hahn, personal communication).
Moreover, in accordance with its role in regulation of
c-Myc stability (Figure 2), CIP2A expression increased
c-Myc protein expression levels in HEK-TERV cells
(Figure 5C).
CIP2A Is Overexpressed in Human Malignancies
The results above indicate that CIP2A could be a putative
novel target for cancer therapeutics; the presumption
being that CIP2A expression is distinguishable between
nontransformed and cancer tissues. According to our
quantitative RT-PCR analysis, CIP2A mRNA was
expressed at very low levels (< 1% of b-actin mRNA-
expression levels) in the majority of the 21 nonmalignant
samples, with the exception of bone marrow, prostate,
testis, cerebellum, and brain (Figure 6A). To compare the
protein levels of CIP2A between nonmalignant and malig-
nant cells, whole-cell lysates of different cell types were
immunoblotted for CIP2A. Consistent with Figure 6A,
very low levels of CIP2A protein was detected in human
epidermal keratinocytes (HEK), nontumorigenic MEFs,
and immortalized NIH3T3 mouse fibroblasts (Figure 6B
and data not shown). However, CIP2A protein was ex-
pressed at high levels in both HeLa cells and in HT-1080
fibrosarcoma cells, indicating that CIP2A expression
may correlate with the tumorigenic potential of cells. Ac-
cordingly, analysis of CIP2A mRNA from low-passage
cell lines derived from human head-and-neck squamous
cell carcinomas (HNSCC), revealed a statistically signifi-
cant overexpression of CIP2A mRNA in 36 HNSCC cell
lines, as compared to normal human epidermal keratino-
cytes (Figure 6C). Importantly, immunohistochemical
Figure 5. CIP2A Promotes Ras-Elicited Foci Formation in
Mouse Embryo Fibroblasts and Transforms Human Cells
(A) Spontaneously immortalized mouse embryo fibroblasts (MEFs)
were infected with recombinant retroviruses encoding RasV12,
CIP2A, or combinations of those, and their ability to form multilayer
foci was quantitated after 14 days. Shown ismean foci number of three
replicate plates from a representative experiment. The experiment was
performed twice with similar results.
(B) Anchorage-independent growth in soft agar of HEK-TERV cells
expressing either lentiviral CIP2A or LacZ. Shown is mean +SD of
number of colonies from 12 plates and from a representative experi-
ment. *p = 0.037, Student’s t test. The experiment was repeated twice
with similar results by using HEK-TERV cells from independent lentivi-
ral infections.
(C) Western blot analysis of endogenous c-Myc expression levels from
HEK-TERV cells expressing either lentiviral CIP2A or LacZ. The exper-
iment was repeated twice with similar results by using cells from inde-
pendent lentiviral infections.(IHC) staining of HNSCC tumors confirmed high expres-
sion of CIP2A protein in 11 out of 14 HNSCC tumor sam-
ples, whereas 9 nonmalignant tissues from the oral cavity
were all negative for CIP2A immunoreactivity (Figure 6D).
Furthermore, staining of the same tissue sample with the
control IgG did not demonstrate any immunoreactivity
(Figure 6D). In HNSCC tissue, CIP2A protein was detected
in the tumor cells, whereas the stroma was mostly nega-
tive (see arrows in Figure 6D).
To further evaluate the observation of CIP2A expression
in HNSCCs, CIP2A protein expression was analyzed in
a mouse model of HNSCC (Lu et al., 2006). In this model,
DMBA-initiated TGFbRII/ mice develop HNSCC that
displays pathology indistinquishable from that of human
and has complete penetrance with some tumors pro-
gressing to metastases (Lu et al., 2006). Evaluation of
CIP2A immunoreactivity by IHC in buccal tissue samples
from wild-type mice, as well as mutant mice displaying
either epithelial hyperplasia (4 weeks after DMBA initia-
tion) or full-blown malignant transformation (15–25 weeks
after DMBA initiation), revealed that both hyperplastic
(5 out of 8) and HNSCC tissues (10 out of 12) clearly dis-
played enhanced expression of CIP2A when compared
to DMBA-treated wild-type animals (Figure 6E). Moreover,
in good agreement with the human HNSCC samples,
CIP2A was predominantly expressed in tumor cells,
whereas the stromal cells were negative for CIP2A (Fig-
ures 6D and 6E).
In addition to HNSCC, colon cancer is a human malig-
nancy associated with increased Ras signaling and loss
of TGF-b signaling (Grady and Markowitz, 2002). There-
fore, CIP2A expression was analyzed from 43 human
colon cancer samples and 5 control samples from normal
colon by RT-PCR. In accordance with the HNSCC data,
CIP2A mRNA was significantly overexpressed in human
colon cancer tissues as compared to control tissues
(Figure 6F).
Together, these results demonstrate that CIP2A is
expressed at low levels in most of the nonmalignant
tissues, but its expression is enhanced in malignant cells
in vivo. Moreover, these results identify HNSCC and colon
cancer as human malignancies associated with increased
CIP2A expression.
CIP2A Enhances Malignant Growth
and Tumorigenesis of HNSCCs
Our results indicate a role for CIP2A in the pathogenesis of
humanmalignancies. To confirm that the cellular functions
of CIP2A described in this study are not restricted to HeLa
cells, three different low-passage HNSCC cell lines
(Lansford et al., 1999) were transfected with CIP2A siRNA
and analyzed for c-Myc protein levels by western blotting.
CIP2A depletion resulted in a clear downregulation of
c-Myc protein levels in all of the HNSCC cell lines
(Figure 7A). Importantly, analysis of c-Myc immunoprecip-
itates revealed that CIP2A depletion also increased
c-Myc-associated PP2A phosphatase activity in HNSCC
cell lines (Figure 7B).Cell 130, 51–62, July 13, 2007 ª2007 Elsevier Inc. 57
Figure 6. CIP2A Is Overexpressed in
Head and Neck Squamous Cell
Carcinomas
(A) CIP2A-mRNA expression was quantitated
by quantitative RT-PCR analysis from normal
tissue samples. CIP2A expression is presented
relative to b-actin.
(B) Western blot analysis of CIP2A protein
expression from human epidermal keratino-
cytes (HEK), mouse NIH3T3 fibroblasts, HeLa,
and fibrosarcoma HT-1080 cell lines.
(C) mRNA expression analysis of CIP2A from
HNSCC (n = 36) and human epidermal kerati-
nocyte (control) cells (n = 6) as determined by
quantitative RT-PCR. CIP2A-mRNA expression
is presented relative to b-actin. *p = 0.012,
Mann-Whitney U test.
(D) Immunohistochemical staining of HNSCC
tissues (n = 14) and nonmalignant control
tissues (CTL; n = 9) for CIP2A expression. Note
that positive staining of tumor cells contrasts
with the negative stromal compartment of the
HNSCC (indicated by arrows). IgG, control
rabbit serum; CIP2A +, positive CIP2A staining.
(E) Immunohistochemical staining of CIP2A in
buccal tissue from TGFbRII+/+ (WT) mice or
TGFbRII/ mice 4 weeks (hyperplasia) and
20 weeks (HNSCC) after DMBA initiation. The
arrows highlight the lack of stromal CIP2A stain-
ing. CIP2A+, positive CIP2A staining.
(F) Quantitative RT-PCR analysis of CIP2A-
mRNA expression in colon cancer tissues and
in nonmalignant colon tissues (control). Shown
is mean expression of samples +S.D. *p < 0.05,
Mann-Whitney U test.To examine the role of CIP2A in the regulation of
HNSCC cell proliferation, UT-SCC-7 and UT-SCC-9 cell
lines were subjected to CIP2A-siRNA transfection and
dense foci formation of these cell lines was monitored
for 10 days. In both cell lines, depletion of CIP2A resulted
in a significant reduction in foci formation (Figure 7C).
Importantly, CIP2A depletion also significantly reduced
anchorage-independent growth of both UT-SCC-7 and
UT-SCC-9 cells in soft agar 21 days after transfection
(Figure 7D). Consistent with the demonstrated specificity
of CIP2A siRNAs in HeLa cells (Figures 2A, 2B, 3B, and
S4), two independent CIP2A siRNAs yielded a similar inhi-
bition in soft-agar growth of UT-SCC-9 cells (Figure 7E).
Finally, to assess the role of CIP2A for in vivo tumor
growth of UT-SCC cells, both UT-SCC-7 and UT-SCC-9
cells transfected with CIP2A or scrambled siRNAs were
injected into the back of severe combined immunodefi-
ciency (SCID) mice. Consistent with all the other data
presented in this work indicating the importance of
CIP2A for malignant cell growth and tumor progression,
only three out of five and two out of six mice injected
with CIP2A-siRNA transfected UT-SCC-7 and UT-SCC-9
cells, respectively, developed palpable tumors at day 65
when the experiment was terminated (Figure 7F). More-
over, CIP2A siRNA reduced the average size of tumors
with both of the UT-SCC cells, as compared to scrambled
siRNA transfected cells (Figure 7F).58 Cell 130, 51–62, July 13, 2007 ª2007 Elsevier Inc.These results confirm that the role of CIP2A in the regu-
lation of c-Myc protein levels, c-Myc-associated PP2A
activity, and in malignant cell growth are not restricted to
HeLa cells but can be recapitulated in low-passage can-
cer cells derived from clinical tumor samples. Together
with the transforming capacity of CIP2A (Figure 5B) and
increased expression in HNSCC and in colon cancer
(Figures 6D and 6F), these findings strongly support an
oncogenic role of CIP2A in human malignancies.
DISCUSSION
Current evidence has established the requirement of
PP2A inhibition for malignant transformation (reviewed in
Arroyo and Hahn, 2005; Janssens et al., 2005). However,
only a few reports thus far have presented potential mech-
anisms for the inhibition of PP2A activity in spontaneously
developing human malignancies. In this regard, low-
frequencymutations of PR65 proteins in humanmalignan-
cies have been reported (Calin et al., 2000; Wang et al.,
1998), and BCR/ABL-induced expression of the PP2A
inhibitor SET was recently reported to promote malignant
growth of chronic myelogenous leukemia cells (Neviani
et al., 2005). Considering this evidence, it is clear that
the discovery of CIP2A, a protein of previously unknown
function that inhibits PP2A in human malignancies and
has transforming activity, is important and expands the
Figure 7. CIP2A Promotes c-Myc Stabil-
ity andMalignant Growth in HNSCC Cells
(A) Immunoblotting of c-Myc protein levels in
HNSCC cells (UT-SCC) 72 hr after transfection
with scrambled or CIP2A.1 siRNA.
(B) The indicated UT-SCC cell lines were trans-
fected for 72 hr with scrambled or CIP2A.1
siRNA and then subjected to c-Myc immuno-
precipitation and PP2A activity assay. Shown
are mean values +SD from two independent
experiments.
(C) Dense foci formation on a monolayer of UT-
SCCs transfected with scrambled or CIP2A.1
siRNA 10 days after replating was quantitated
by Image J software. Shown are average +
SD of three experiments. *p < 0.05, Student’s
t test.
(D) Anchorage-independent growth in soft agar
of UT-SCCs transfected with scrambled or
CIP2A.1 siRNA at day 21. Shown is the average
+SD of six replicate plates. *p < 0.05, Student’s
t test.
(E) Anchorage-independent growth in soft agar
of UT-SCC-9 cells transfected with two inde-
pendent CIP2A-targeting siRNAs (CIP2A.1 or
CIP2A.2) or scrambled siRNA was quantitated
at day 21. Shown is the average +SD of six rep-
licate plates. *p < 0.05, Student’s t test.
(F) UT-SCC-7 or UT-SCC-9 cells transfected
for 72 hr with either scrambled or CIP2A.1
siRNAs were injected subcutaneously into the
back of SCID mice and monitored for 59 days
for the appearance tumors. Shown are the
number of palpable tumors and mean +SEM
of tumor weights.general understanding of the mechanisms critical for
cancer progression. In addition to its role in cancer, it is
plausible that CIP2A regulation of c-Myc stability and
cell growth could impact other conditions that rely on
c-Myc function, for example, stem cell renewal (Gandaril-
las and Watt, 1997; Honeycutt and Roop, 2004). There-
fore, the reported function of CIP2A in regulating c-Myc
stability further expands the general importance of this
work.
Based on previously published work, it is well estab-
lished that c-Myc S62 is an in vivo target for PP2A and
that phosphorylation of S62 protects c-Myc from proteo-
lytic degradation both in mammals and in yeast (Arnold
and Sears, 2006; Escamilla-Powers and Sears, 2007;
Yeh et al., 2004). Therefore, our results are fully consistent
with the proposed role of CIP2A as a PP2A inhibitor that
stabilizes c-Myc protein (Arnold and Sears, 2006; Yeh
et al., 2004). Importantly, our results indicate that among
the PP2A substrates, CIP2A selectively targets the
c-Myc-associated PP2A complex. These conclusions
are supported by the data that CIP2A binds directly to
c-Myc (Figure 3D) and that its depletion does not affect
MEK1,2 phosphorylation or MDM2-associated PP2A
activity (Figures 2C and 3B). Moreover, our findings dem-
onstrate that the c-Myc S62 mutations, which have no
effect on the interaction between PP2A and c-Myc (Arnoldand Sears, 2006), drastically impaired the CIP2A-c-Myc
interaction (Figure 3E). Therefore, it seems evident that
CIP2A is not recruited to c-Myc via its interaction with
PP2A but directly binds to c-Myc through recognition of
the S62 site and subsequently inhibits c-Myc-associated
PP2A activity. Taken together, our results suggest a hith-
erto unrecognized mechanism for localized inhibition of
PP2A activity, whereby the in vivo specificity of PP2A is
determined by direct binding of a PP2A inhibitor to the
PP2A substrate. In the future, it would be of great interest
to study if CIP2A binding to c-Myc only determines its
in vivo specificity or if it is also a prerequisite for CIP2A’s
function as a PP2A inhibitor protein.
Our results demonstrate that depletion of CIP2A in-
creases c-Myc-associated PP2A activity without affecting
the PP2A-c-Myc interaction (Figures 3B and 3C). More-
over, the increase in c-Myc-associated PP2A activity
was observed both in cells by enhanced dephosphoryla-
tion of c-Myc S62 (Figure 3A) and in vitro by using
a PP2A substrate unrelated to c-Myc (Figure 3B). To-
gether these results strongly indicate that the catalytic
activity of PP2Ac per se is inhibited by CIP2A. Recently
published structures of the PP2A holoenzyme suggest
that the structural arrangement of the PP2A B-C subunit
interface and the conformational flexibility of the PR65/A
subunit make the PP2A complex susceptible to structuralCell 130, 51–62, July 13, 2007 ª2007 Elsevier Inc. 59
changes that may inhibit substrate hydrolysis by PP2Ac or
alter the substrate specificity (Cho and Xu, 2007; Xu et al.,
2006). It is possible that allosteric regulation of the PP2A
complex structure could mediate inhibition of PP2A activ-
ity by CIP2A binding. However, as the exact molecular
mechanism of PP2A inhibition by CIP2A remains a matter
of speculation at this point, future research is needed to
untangle this possibility.
On the cellular level, our results show that CIP2A is not
essential for cell-cycle progression or cell viability but sup-
ports malignant cell growth and c-Myc-mediated gene
expression (Figure 4 and data not shown). Importantly,
we demonstrate that CIP2A expression transforms
HEK-TERV cells immortalized by Ras, TERT, and large-T
antigen (Figure 5B) and that CIP2A is sufficient to induce
tumorigenic conversion of spontaneously immortalized
murine cells in combination with Ras (Figure 5A). These
results strongly implicate CIP2A as a protein that cooper-
ates with other oncoproteins in cellular transformation.
Moreover, we show that CIP2A expression is already
induced in premalignant HNSCC tissue in response to
a combination of oncogenic Ras signaling and inhibition
of the TGF-b tumor suppressor pathway (Figure 6F).
These results further support the role of CIP2A as an
oncoprotein involved in early cellular transformation and
suggest functional cooperation between Ras and CIP2A
at least in HNSCC development.
In addition to their biological significance, the results
presented in this work strongly indicate that CIP2A inhibi-
tion could provide an opportunity for targeted degradation
of c-Myc in cancer cells, making CIP2A a candidate target
protein for future cancer therapeutics. Importantly, inhibi-
tion of CIP2A should decrease c-Myc levels in cancer cells
regardless of the cause of c-Myc protein overexpression
(Sears, 2004). Moreover, by focusing on a tumor-specific
protein, such as CIP2A, the controversy surrounding the
inability to directly regulate PP2A and/or c-Myc in
normal tissue due to their requirement for normal cellular
function would be alleviated (Gotz et al., 1998;
Pelengaris et al., 2002).
Taken together, this study identifies CIP2A as a cellular
PP2A inhibitor that inhibits proteolytic degradation of
c-Myc. Moreover, we demonstrate that CIP2A is important
for the maintenance of the malignant cellular phenotype
and that overexpression of CIP2A transforms HEK-TERV
cells. Importantly, CIP2A is overexpressed in two com-
mon human malignancies, HNSCC and colon cancer.
Together, these results demonstrate that CIP2A acts as
a human oncoprotein that inhibits PP2A in human malig-
nancies. However, even though our current results sug-
gest that inhibition of c-Myc-associated PP2A activity is
one of the mechanisms by which CIP2A supports malig-
nant cellular growth, we cannot rule out that CIP2A might
exert its oncogenic properties also through other as yet
unidentified mechanisms. Therefore, further elucidation
of the molecular functions of CIP2A, both in its regulation
of c-Myc stability and in other signaling events potentially
regulated by the PP2A-CIP2A interaction, will be of great60 Cell 130, 51–62, July 13, 2007 ª2007 Elsevier Inc.importance. In addition, identification of the physiological
role of CIP2A and its potential involvement in nonma-
lignant cellular processes such as stem cell renewal or




HeLa, HT-1080, HEK-293, and 3T3 cells were obtained from ATCC.
Spontaneously immortalized mouse embryo Fibroblasts was estab-
lished as described previously (Dietrich et al., 2004). Human HNSCC
cell lines were established at the time of operation from HNSCCs
(Lansford et al., 1999). HEK-TERV cells were a generous gift from Pro-
fessor W.C. Hahn (Chen et al., 2004, 2005). Normal HEK were estab-
lished from skin samples (generous gift from Professor J. Peltonen)
and cultured in Keratinocyte Basal Medium 2 (KBM-2), supplemented
with SingleQuots (Cambrex Bioscience).
siRNA Transfections
One hundred nanomolars of double-stranded siRNA oligonucleotides
(for siRNA sequences, see Supplemental Data) were transfected with
Oligofectamine reagent (Invitrogen) according to the manufacturer´s
instructions. Four silent mutations were introduced in the CIP2A.1
siRNA-binding region of CIP2A flag construct to create the CIP2A
rescue plasmid using QuikChange II site-directed mutagenesis kit
(Stratagene) (for sequence information, see Supplemental Data). In
rescue experiments, 2 mg of rescue plasmid was transfected 24 hr after
siRNA transfection using Lipofectamine 2000 (Invitrogen).
Anchorage-Independent Growth and Foci Formation Assays
For HeLa cell foci formation and anchorage-independent growth
assays, 4 3 105 cells were seeded on 10 cm plates 48 hr after siRNA
transfection. Soft-agar assays were performed in medium containing
10% fetal bovine serum as described (Chen et al., 2005). The number
and size of colonies were analyzed using ImageJ 1.33u software from
microscopy images (35 magnification). Anchorage-independent colo-
nies were classified according to a number between 200—10,000
pixels.
For foci formation assays in MEFs, 200 or 500 cells of the retrovirally
transduced MEFs were plated with 8.3 3 105 NIH3T3 cells as feeders
per well in a 6-well plate. Cells were grown for 1–2 weeks. Methanol-
fixed cells were stained with Giemsa. Foci numbers were calculated
per 100 infected cells.
In Vivo Tumor Formation
For the mouse experiments, 3 3 106 siRNA transfected cells were
injected subcutaneously into the flank or back of immunocompro-
mised mouse. Tumor formation was evaluated every third day by pal-
pation, and the size of the palpable tumors wasmeasured by precision
instrument or by weighing the tumors at the end of the experiment.
Virus Production
Lentiviral clones of CIP2A and lacZ were transfected into 293FT cells
with ViraPower packaging mix (Invitrogen Life Technologies). Super-
natants were harvested 48 hr after transfection, sterile filtered, and
stored at 80C. HEK-TERV cells were infected for 24 hr with viral
supernatant at MOI 1000, and selection was begun 48 hr later with
Zeocin (100 mg/ml) (Invitrogen Life Technologies). Clones were verified
for transgene expression after 10 days and analyzed for anchorage-
independent growth in soft agar. For retroviral infections, virus propa-
gation and purification were performed as previously published
(Morgenstern and Land, 1990).
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
one table, and five figures and can be found with this article online at
http://www.cell.com/cgi/content/full/130/1/51/DC1/.
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